Brief Summary:
A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole versus placebo for 6 weeks in children (age 6-17) diagnosed with Tourette Disorder according to DSM IV criteria. The primary efficacy measure will be the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS) at 6 weeks.
Tourette Syndrome | Drug: pramipexole immediate release (IR) Drug: Placebo | Phase 2 |
Layout table for study information
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 63 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-blind, Placebo-controlled, Flexible Dose Study to Evaluate Efficacy and Safety of Pramipexole Immediate Release (0.125-0.5mg/Day) Versus Placebo for 6 Weeks in Children and Adolescents (Age 6-17 Inclusive) Diagnosed With Tourette Disorder According to DSM IV Criteria. |
Study Start Date : | January 2008 |
Actual Primary Completion Date : | June 2009 |
Resource links provided by the National Library of Medicine
Pramipexole | Drug: pramipexole immediate release (IR) |
Placebo Comparator: Placebo | Drug: Placebo |
Primary Outcome Measures :
- Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale [ Time Frame: baseline 6 weeks ]
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
Analysis was adjusted for baseline total tic score and age as linear covariates.
Secondary Outcome Measures :
- Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 1 [ Time Frame: baseline 1 week ]
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50
- Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 2 [ Time Frame: baseline and 2 weeks ]
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50
- Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 3
[ Time Frame: baseline and 3 weeks ]
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50
- Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale at Week 4 [ Time Frame: baseline and 4 weeks ]
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50
- Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 6 [ Time Frame: baseline and 6 weeks ]
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)
- Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to
Motor and Phonic Tics at Week 1 [ Time Frame: baseline 1 week ]
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)
- Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 2 [ Time Frame: baseline and 2 weeks ]
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)
- Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 3 [ Time Frame: baseline and 3 weeks ]
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)
- Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale Due to Motor and Phonic Tics at Week 4 [ Time Frame: baseline
4 weeks ]
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe)
- Clinical Global Impressions - Improvement at 1 Week [ Time Frame: baseline and Week 1 ]
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
- Clinical Global Impressions - Improvement at Week 2 [ Time Frame: baseline and Week 2 ]
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
- Clinical Global Impressions - Improvement at Week 3 [ Time Frame: baseline
and Week 3 ]
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
- Clinical Global Impressions - Improvement at Week 4 [ Time Frame: baseline and Week 4 ]
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
- Clinical Global Impressions - Improvement at Week 6 [ Time Frame: baseline and Week 6 ]
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
- Clinical Global Impressions - Severity of Illness at Week 1 [ Time Frame: baseline and Week 1 ]
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.
- Clinical Global Impressions - Severity of Illness at Week 2
[ Time Frame: baseline and Week 2 ]
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.
- Clinical Global Impressions - Severity of Illness at Week 3 [ Time Frame: baseline and Week 3 ]
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.
- Clinical Global Impressions - Severity of Illness at Week 4 [ Time Frame: baseline and Week 4 ]
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.
- Clinical Global Impressions - Severity of Illness at Week 6 [ Time Frame: baseline and Week 6 ]
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (the most extremely ill patients). Improved, Unchanged and Worsened responses correspond to changes from baseline of: -2 or less, -1 to +1, and 2 or greater.
- Patient Global
Impression at Week 1 [ Time Frame: baseline and Week 1 ]
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
- Patient Global Impression at Week 2 [ Time Frame: baseline and Week 2 ]
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
- Patient Global Impression at Week 3 [ Time Frame: baseline and Week 3 ]
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
- Patient Global Impression at Week 4 [ Time Frame: baseline and Week 4 ]
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
- Patient Global Impression at Week 6 [ Time Frame: baseline and Week 6 ]
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
- Clinically Significant Abnormalities in Vital Signs (Orthostatic
Reaction and Pulse Rate), and Serum Chemistry. [ Time Frame: baseline and Week 6 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study: | 6 Years to 17 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male of female patients 6-17 yrs.
- Written informed consent.
- Diagnosed with Tourette's Disorder with a > or equal to 22 on the Total Tic Score at baseline.
- Diagnosed with Tourette's Disorder when administering the Diagnostic Interview Schedule for Children.
- Having at least 1 tic/day.
- Women of childbearing age must have a negative serum pregnancy test at screening and must use a medically accepted contraceptive method.
- Either a newly diagnosed patient or a patient diagnosed with Tourette's Disorder who can safely discontinue treatment.
- Having a body weight of > or equal to 20 kg (44 lbs).
Exclusion Criteria:
- Any women of childbearing age having a positive serum pregnancy test at screening.
- Patients who have clinically significant renal disease or serum creatinine greater than 1.0 mg/dL at screening.
- Lab results at screening: hemoglobin below lower limit of normal which is determined to be clinically significant; Thyroid Stimulating Hormone (TSH), triiodothyronine (T3) or thyroxine (T4) clinically significant; clinically significant abnormalities in labs.
- Other clinically significant metabolic-endocrine, hematological, gastrointestinal disease, pulmonary disease which would preclude the patient from participating in this study.
- History of Schizophrenia or any psychotic disorder, history of mental disorders or any present Axis I psychiatric disorder according to Diagnostic and Statistic Manual of Mental Disorders Fourth Edition (DSM-IV) requiring any medical therapy except for patients with a diagnosis of attention deficit hyperactivity disorder (ADHD) or obsessive-compulsive disorder (OCD) who are not on therapy.
- History of/or clinical signs of epilepsy or seizures other than fever related seizures in early childhood.
- History of/or clinical signs of any malignant neoplasm.
- Allergic response to pramipexole.
- Had previous treatment with dopamine agonists other than pramipexole within 14 days prior to baseline visit.
- Had any other medical treatment for Tourette's Disorder besides the study medication within 28 days prior to baseline visit.
- Had withdrawal symptoms of any medication at screening or at the baseline visit.
- Having a Kaufman Brief Intelligence Test (KBIT IQ) score <70 at screening.
- Having a children's Yale-Brown obsessive-compulsive scale (CY-BOCS) score of >15 at baseline.
- Patients who meet criteria for Restless Legs Syndrome and or Periodic Limb Movement disorder.
- Patients with severe asthma.
- Patients that have initiated psychotherapy for Tourette's Disorder, OCD or ADHD within 3 mths of starting the trial.
- Patients receiving psychological, cognitive and/or behavioral treatments greater than 3 mths prior to start of trial for Tourette's Disorder, OCD, and/or ADHD who will have changes in treatment plan.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00558467
Layout table for location information
United States, Florida | |
248.644.0026 Boehringer Ingelheim Investigational Site | |
Bradenton, Florida, United States | |
248.644.0025 Boehringer Ingelheim Investigational Site | |
Tampa, Florida, United States | |
United States, Georgia | |
248.644.0006 Boehringer Ingelheim Investigational Site | |
Columbus, Georgia, United States | |
United States, Illinois | |
248.644.0012 Boehringer Ingelheim Investigational Site | |
Chicago, Illinois, United States | |
United States, Massachusetts | |
248.644.0005 Boehringer Ingelheim Investigational Site | |
Cambridge, Massachusetts, United States | |
United States, New York | |
248.644.0003 Boehringer Ingelheim Investigational Site | |
Manhasset, New York, United States | |
248.644.0009 Boehringer Ingelheim Investigational Site | |
New York, New York, United States | |
248.644.0018 Boehringer Ingelheim Investigational Site | |
New York, New York, United States | |
248.644.0013 Boehringer Ingelheim Investigational Site | |
Orangeburg, New York, United States | |
United States, Oklahoma | |
248.644.0029 Boehringer Ingelheim Investigational Site | |
Oklahoma City, Oklahoma, United States | |
United States, Rhode Island | |
248.644.0010 Boehringer Ingelheim Investigational Site | |
Providence, Rhode Island, United States | |
United States, Tennessee | |
248.644.0030 Boehringer Ingelheim Investigational Site | |
Memphis, Tennessee, United States | |
United States, Texas | |
248.644.0008 Boehringer Ingelheim Investigational Site | |
Houston, Texas, United States | |
United States, Virginia | |
248.644.0023 Boehringer Ingelheim Investigational Site | |
Norfolk, Virginia, United States | |
Germany | |
248.644.49001 Boehringer Ingelheim Investigational Site | |
Hannover, Germany | |
248.644.49004 Boehringer Ingelheim Investigational Site | |
Ulm, Germany |
Boehringer Ingelheim
Layout table for investigator information
Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim |
Layout table for additonal information
Responsible Party: | Boehringer Ingelheim |
ClinicalTrials.gov Identifier: | NCT00558467 |
Other Study ID Numbers: | 248.644 |
First Posted: | November 15, 2007 Key Record Dates |
Results First Posted: | October 20, 2010 |
Last Update Posted: | May 16, 2014 |
Last Verified: | March 2014 |
Additional relevant MeSH terms:
Layout table for MeSH terms
Tourette Syndrome Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Tic Disorders Movement Disorders Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases Genetic Diseases, Inborn Neurodevelopmental Disorders | Mental Disorders Pramipexole Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Antiparkinson Agents Anti-Dyskinesia Agents Dopamine Agonists Dopamine Agents Neurotransmitter Agents |